AbbVie Inc agreed to buy Pharmacyclics Inc in a US$21 billion deal after beating out Johnson & Johnson for control of a blockbuster blood cancer therapy that will help it expand in the lucrative area of oncology.
Under the terms of the transaction, AbbVie will pay US$261.25 per share comprised of a mix of cash and AbbVie equity, the two companies said in a statement yesterday.
The price is 39 percent higher than Pharmacyclics’ closing price on Feb. 24, the day before Bloomberg News reported that the company was considering a deal. The purchase would help AbbVie reduce its reliance on Humira, its best-selling rheumatoid arthritis treatment, while expanding into cancer therapy, one of the most promising areas of drug development.
It would gain control of Imbruvica, an easy-to-use pill that costs about US$100,000 a year, avoids certain serious side effects of chemotherapy and is already approved for four different blood cancer uses.
Pharmacyclics was nearing an agreement to be acquired by Johnson & Johnson, which was discussing a price of about US$250 per share, before AbbVie topped the offer at the last minute, a person with knowledge of the matter said.
The person asked not to be identified as the details are private.
Johnson & Johnson spokeswoman Amy Jo Meyer declined to comment.
Pharmacyclics had net income last year of US$86 million, according to data compiled by Bloomberg. However, sales of Imbruvica are expected to grow to US$3.56 billion in 2018 from US$492 million last year, according to an average of estimates by analysts surveyed by Bloomberg, as it is used in more types of cancer.
While Imbruvica overlaps with one of AbbVie’s top pipeline products, ABT-199, there should be room for both, Bloomberg Intelligence analyst Asthika Goonewardene said.
It might take until next year for ABT-199 to be approved, and while Imbruvica has shown itself to be a preferred drug for many patients, others might benefit from a different therapy, Goonewardene said.
“Given all this, having two dogs in the race may not be a bad thing,” Goonewardene said in an e-mail.
AbbVie said it expects about 58 percent of the deal to be paid in cash, 42 percent in stock and for it to be finalized mid-year.
AbbVie shares closed 1.1 percent higher at US$60.27 in New York.
Since splitting off from parent company Abbott Laboratories in 2013, AbbVie has not completed one of the megadeals that have tempted much of the rest of the drug industry.
It has tried. AbbVie and Shire PLC in October last year agreed to terminate a planned US$52 billion acquisition by AbbVie that would have redomiciled the drugmaker abroad and given it a lower tax rate.
AbbVie pulled its support for the transaction after proposed changes to US rules.
Pharmacyclics is partnered with Johnson & Johnson on Imbruvica. The drug could eventually be used to treat solid tumors.
Pharmacyclics also has a partnership with AstraZeneca PLC to develop the drug for use with a new type of oncology treatment that triggers the body’s immune system to attack tumors.
“We’re looking forward to continuing our collaboration with the team at AbbVie to further develop and commercialize this important therapy [Imbruvica],” Johnson & Johnson said in an e-mailed statement.
purpose: Tesla’s CEO sought to meet senior Chinese officials to discuss the rollout of its ‘full self-driving’ software in China and approval to transfer data they had collected Tesla Inc CEO Elon Musk arrived in Beijing yesterday on an unannounced visit, where he is expected to meet senior officials to discuss the rollout of "full self-driving" (FSD) software and permission to transfer data overseas, according to a person with knowledge of the matter. Chinese state media reported that he met Premier Li Qiang (李強) in Beijing, during which Li told Musk that Tesla's development in China could be regarded as a successful example of US-China economic and trade cooperation. Musk confirmed his meeting with the premier yesterday with a post on social media platform X. "Honored to meet with Premier Li
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Dutch brewing company Heineken NV on Friday announced an investment of NT$13.5 billion (US$414.62 million) over the next five years in Taiwan. The first multinational brewing company to operate in Taiwan, Heineken made the statement at a ceremony held at its brewery in Pingtung County. It also outlined its efforts to make the brewery “net zero” by 2030. Heineken has been in the Taiwanese market for 20 years, Heineken Taiwan managing director Jeff Wu (吳建甫) said. With strong support from local consumers, the Dutch brewery decided to transition from sales to manufacturing in the country, Wu said. Heineken assumed majority ownership and management rights
Microsoft Corp yesterday said that it would create Thailand’s first data center region to boost cloud and artificial intelligence (AI) infrastructure, promising AI training to more than 100,000 people to develop tech. Bangkok is a key economic player in Southeast Asia, but it has lagged behind Indonesia and Singapore when it comes to the tech industry. Thailand has an “incredible opportunity to build a digital-first, AI-powered future,” Microsoft chairman and chief executive officer Satya Nadella said at an event in Bangkok. Data center regions are physical locations that store computing infrastructure, allowing secure and reliable access to cloud platforms. The global embrace of AI